Metabolic genes, a potential predictor of prognosis and immunogenicity of clear cell renal cell carcinoma

Cheng-Jian Ji; Xi-Yi Wei; Liang-Yu Yao; Yi-Chun Wang; Rong Cong; Ning-Hong Song

Metabolic genes, a potential predictor of prognosis and immunogenicity of clear cell renal cell carcinoma

Am J Cancer Res. 2023 Apr 15;13(4):1387-1406. eCollection 2023.

Authors

Cheng-Jian Ji¹, Xi-Yi Wei¹, Liang-Yu Yao¹, Yi-Chun Wang¹, Rong Cong¹, Ning-Hong Song^{1

2}

Affiliations

¹ Department of Urology, The First Affiliated Hospital of Nanjing Medical University Nanjing 210029, Jiangsu, China.
² The Affiliated Kezhou People's Hospital of Nanjing Medical University Kezhou 845350, Xinjiang, China.

PMID: 37168330
PMCID: PMC10164820

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC). Many ccRCCs are diagnosed at an advanced stage due to the lack of early symptoms, with a high mortality rate and a poor prognosis. The occurrence and development of ccRCC are closely related to metabolic disorders. This study aims to explore the relationship between metabolic genes and prognosis, immune microenvironment, and tumor development of ccRCC. Using data from TCGA, GEO, and ArrayExpress, we successfully established a risk model (riskScore) based on 4 metabolic genes (MGs) that can accurately predict the prognosis and immune microenvironment of ccRCCs. In addition, we determined the role of PAFAH2 in suppressing tumor cell proliferation and migration in ccRCC in vitro. Our research may shed new light on ccRCC patients' prognosis and treatment management.

Keywords: Metabolic genes; PAFAH2; TME; ccRCC; prognosis.